These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 30399387

  • 21. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
    Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.
    J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions.
    Cheraghlou S, Levy LL.
    Clin Dermatol; 2020 Oct; 38(6):679-692. PubMed ID: 33341201
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
    Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME.
    Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
    [Abstract] [Full Text] [Related]

  • 28. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [Abstract] [Full Text] [Related]

  • 29. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes.
    Hashimoto H, Ito T, Ichiki T, Yamada Y, Oda Y, Furue M.
    J Clin Med; 2021 Feb 12; 10(4):. PubMed ID: 33673164
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Skin Reactions to Immune Checkpoint Inhibitors.
    Patel AB, Pacha O.
    Adv Exp Med Biol; 2020 Feb 12; 1244():235-246. PubMed ID: 32301018
    [Abstract] [Full Text] [Related]

  • 32. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM, Vryzaki E, Georgiou S.
    Curr Drug Saf; 2019 Feb 12; 14(1):14-20. PubMed ID: 30058498
    [Abstract] [Full Text] [Related]

  • 33. Nivolumab-induced lichenoid penile ulceration and re-emergent mucocutaneous eruption treated with hydroxychloroquine.
    Headd VA, Mathien A, Pei S, Kuraitis D.
    Australas J Dermatol; 2024 Jun 12; 65(4):e97-e99. PubMed ID: 38337182
    [No Abstract] [Full Text] [Related]

  • 34. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A, Shah U, Khine H, Vandergriff T, Froehlich T.
    Melanoma Res; 2017 Apr 12; 27(2):171-173. PubMed ID: 28099367
    [No Abstract] [Full Text] [Related]

  • 35. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
    Diaz-Perez JA, Beveridge MG, Victor TA, Cibull TL.
    J Cutan Pathol; 2018 Jun 12; 45(6):434-438. PubMed ID: 29468713
    [Abstract] [Full Text] [Related]

  • 36. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
    Emonet C, Tétart F, Bauvin O, Cellier L, Courville P, Mignard C, Janela-Lapert R, Lefebvre A, Lachkar S, Lechevalier D, Lagarce L, Carvalho P, Tedbirt B.
    J Immunother; 2018 Jun 12; 46(2):59-63. PubMed ID: 36622668
    [Abstract] [Full Text] [Related]

  • 37. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY.
    Eur J Cancer; 2019 Jul 12; 115():84-87. PubMed ID: 31129384
    [No Abstract] [Full Text] [Related]

  • 38. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.
    Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.
    Am J Surg Pathol; 2017 Oct 12; 41(10):1381-1389. PubMed ID: 28817405
    [Abstract] [Full Text] [Related]

  • 39. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
    Dasanu CA.
    J Oncol Pharm Pract; 2019 Dec 12; 25(8):2052-2055. PubMed ID: 30782092
    [Abstract] [Full Text] [Related]

  • 40. [Adverse cutaneous drug reactions].
    Rupec RA, Boneberger S, Ruzicka T.
    Dtsch Med Wochenschr; 2007 Dec 12; 132(50):2685-94. PubMed ID: 18058660
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.